|Day Low/High||145.84 / 149.61|
|52 Wk Low/High||125.84 / 197.00|
--One-year study continues to support positive safety and tolerability profile for ubrogepant--
DUBLIN and SAN FRANCISCO, Oct. 16, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines,...
DUBLIN, Oct. 11, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic Surgery (ASDS) meeting in Phoenix, AZ from October...
DUBLIN, Oct. 8, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it will present data from its gastroenterology portfolio at the American College of Gastroenterology Annual Scientific Meeting (ACG),...
- New programs will evaluate the safety and efficacy of brazikumab (an investigational drug) and the potential correlation between biomarkers and patient outcomes with brazikumab
DUBLIN, Oct. 4, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting ® treatment received FDA clearance to treat the submandibular area.
Aegon's subsidiary Transamerica today announces an agreement that would resolve litigation challenging certain monthly deduction rate adjustments on universal life insurance policies in the United States.
Bigger, bolder JUVÉDERM® campaign seeks to make JUVÉDERM® a household name for consumers
DUBLIN, Oct. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release third quarter 2018 financial results on Tuesday, October 30, 2018, prior to the open of U.
Straying from these names could land you in quicksand as the 4th quarter begins.
Allergan Foundation pledges $2,000,000 to support breast health research
Aegon expects a one-time benefit to capital generation of approximately USD 1 billion as a result of the merger of two legal entities.
Aegon will repurchase 24,133,950 common shares to neutralize the dilutive effect of the 2018 interim stock dividend.
The entrance of more competition for Botox Cosmetic could expand the market, the drugmaker's top executive says at the Wells Fargo Healthcare Conference in Boston.
Today, US subsidiaries of Aegon reached a settlement with the Securities and Exchange Commission (SEC) in the matter of the operation and implementation of asset management quantitative models by Aegon's US asset management operations, and related...
A 'bullish perfect storm of technical factors' is powering the recent strength in large-cap pharma stocks, says Evercore ISI's Rich Ross.
Here's what you need to know now for Thursday, Aug. 23.
Let's check out the charts again so see how far this advance might carry.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGN, DSS, ENDP, ICUI, PIH, SPB, SPPI, WAAS, YRD Downgrades: BMA, BRT, ELSE, FRBK, HAE, HSKA, JD, MATW, TCMD, TSG Initiations: ALT, TRTX Read on to get TheStreet Quant Ratings' detailed report:
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
Net income amounts to EUR 491 million supported by increase in underlying earnings Underlying earnings increase by 2% to EUR 1,064 million, or 10% on constant currencies driven by expense savings, a higher investment margin in the Netherlands, performance...
Aegon has agreed to sell its businesses in Czech Republic and Slovakia for EUR 155 million to NN Group.
The Dow Jones Industrial Average declined by 125 points on Monday.
The first is the ISE Equity Ratio which chimed in at 213%, its first reading over 200% since January 26.
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.